Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, John M. Kane, Mark Agulnik, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 7, pp. 815-833
Open Access | Times Cited: 964

Showing 1-25 of 964 citing articles:

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S. Gordon, Sunil Sharma, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 26, pp. 3119-3125
Open Access | Times Cited: 812
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
Patrick Schöffski, Sant P. Chawla, Robert G. Maki, et al.
The Lancet (2016) Vol. 387, Iss. 10028, pp. 1629-1637
Open Access | Times Cited: 704
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Guoshuang Shen, Fangchao Zheng, Dengfeng Ren, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 484
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter Thuss‐Patience, Manish A. Shah, Atsushi Ohtsu, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 5, pp. 640-653
Closed Access | Times Cited: 464
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial
Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 8, pp. 1148-1159
Open Access | Times Cited: 375
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 5, pp. 631-639
Closed Access | Times Cited: 364
Current clinical management of gastrointestinal stromal tumor
Kazuya Akahoshi, Masafumi Oya, Tadashi Koga, et al.
World Journal of Gastroenterology (2018) Vol. 24, Iss. 26, pp. 2806-2817
Open Access | Times Cited: 331
Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis
Roger Hilfiker, André Meichtry, Manuela Eicher, et al.
British Journal of Sports Medicine (2017) Vol. 52, Iss. 10, pp. 651-658
Open Access | Times Cited: 315
Indications, results, and clinical impact of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline – Updated January 2017
Jean‐Marc Dumonceau, Pierre H. Deprez, Christian Jenssen, et al.
Endoscopy (2017) Vol. 49, Iss. 07, pp. 695-714
Open Access | Times Cited: 315
Improved survival using specialized multidisciplinary board in sarcoma patients
Jean‐Yves Blay, Pauline Soibinet, Nicolas Penel, et al.
Annals of Oncology (2017) Vol. 28, Iss. 11, pp. 2852-2859
Open Access | Times Cited: 304
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol, Michael A. Postow, Marianne Davies, et al.
Cancer Treatment Reviews (2017) Vol. 58, pp. 70-76
Open Access | Times Cited: 264
Gastrointestinal Stromal Tumors
Margaret von Mehren, Heikki Joensuu
Journal of Clinical Oncology (2017) Vol. 36, Iss. 2, pp. 136-143
Open Access | Times Cited: 250
Surgery in reference centers improves survival of sarcoma patients: a nationwide study
Jean‐Yves Blay, Charles Honoré, Eberhard Stoeckle, et al.
Annals of Oncology (2019) Vol. 30, Iss. 7, pp. 1143-1153
Open Access | Times Cited: 248
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 28, pp. 3198-3206
Closed Access | Times Cited: 236
Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
Takehito Shukuya, David P. Carbone
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 7, pp. 976-988
Open Access | Times Cited: 224
The role of endoscopy in subepithelial lesions of the GI tract
Ashley L. Faulx, Shivangi Kothari, Ruben D. Acosta, et al.
Gastrointestinal Endoscopy (2017) Vol. 85, Iss. 6, pp. 1117-1132
Open Access | Times Cited: 218
Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study
Akira Kawai, Nobuhito Araki, Hideshi Sugiura, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 4, pp. 406-416
Closed Access | Times Cited: 208
A systematic review of rehabilitation and exercise recommendations in oncology guidelines
Nicole L. Stout, Daniel Santa Mina, Kathleen Doyle Lyons, et al.
CA A Cancer Journal for Clinicians (2020) Vol. 71, Iss. 2, pp. 149-175
Open Access | Times Cited: 201
Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network
Gonzague de Pinieux, Marie Karanian, François Le Loarer, et al.
PLoS ONE (2021) Vol. 16, Iss. 2, pp. e0246958-e0246958
Open Access | Times Cited: 199
The Distress Thermometer: Cutoff Points and Clinical Use
Alexandra Cutillo, Erin O’Hea, Sharina D. Person, et al.
Oncology nursing forum (2017) Vol. 44, Iss. 3, pp. 329-336
Open Access | Times Cited: 179
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial
Sandro Pasquali, Sara Pizzamiglio, Nathan Touati, et al.
European Journal of Cancer (2019) Vol. 109, pp. 51-60
Closed Access | Times Cited: 172
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group
Carol J. Swallow, D. Strauß, Sylvie Bonvalot, et al.
Annals of Surgical Oncology (2021) Vol. 28, Iss. 12, pp. 7873-7888
Open Access | Times Cited: 169
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
Janice M. Mehnert, Andréa Varga, Marcia S. Brose, et al.
BMC Cancer (2019) Vol. 19, Iss. 1
Open Access | Times Cited: 168
Synovial Sarcoma: A Clinical Review
Aaron Gazendam, Snežana Popović, Sohaib Munir, et al.
Current Oncology (2021) Vol. 28, Iss. 3, pp. 1909-1920
Open Access | Times Cited: 161
Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
Silvia Stacchiotti, Anna Maria Frezza, Jean‐Yves Blay, et al.
Cancer (2021) Vol. 127, Iss. 16, pp. 2934-2942
Open Access | Times Cited: 155
Page 1 - Next Page

Scroll to top